Navigation Links
Cell Therapeutics, Inc. Announces Institutional Investors Purchase $30 Million of Preferred Stock and Warrants
Date:6/29/2011

SEATTLE, June 30, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. (Nasdaq and MTA:CTIC) (the "Company") today announced that it has entered into an agreement to sell, subject to customary closing conditions, $30 million of shares of its Series 13 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to six institutional investors. Each share of Series 13 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 588 shares of common stock at a conversion price of $1.70 per share of common stock, for a total of approximately 17,647,059 shares of common stock.

In connection with the offering, the investors received warrants to purchase up to 8,820,000 shares of common stock. The warrants have an exercise price of $2.15 per warrant share, for total potential additional proceeds to the Company of approximately $19 million upon exercise of the warrants for cash. The warrants are exercisable beginning six months and one day after the date of issuance and expire five years and one day after the date of issuance.

The Company intends to use the net proceeds from the offering for general corporate purposes, which may include, among other things, paying interest on and/or retiring portions of its outstanding debt, funding research and development, preclinical and clinical trials, the preparation and filing of new drug applications and general working capital. The Company may also use a portion of the net proceeds to fund possible investments in, or acquisitions of, complementary businesses, technologies or products. The Company has recently engaged in limited discussions with third parties regarding such investments or acquisitions, but has no current agreements or commitments with respect to any investment or acquisition.

Shares of the Series 13 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
2. Serina Therapeutics, Inc. Closes $9.5 Million Financing Round
3. Cancer Research UK Signs Deal With Centella Therapeutics, Inc. to Launch Clinical Development of Radiotherapy-Enhancing Drug
4. Cell Therapeutics, Inc. Announces Institutional Investors Purchase Approximately $16.0 Million of Preferred Stock and Warrants
5. Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results
6. Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Maintains Target Price of $6.50
7. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
8. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2010 Financial Results on February 16
9. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
10. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®
11. Veteran Pharmaceutical Executives Form New American Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... DIEGO and BOSTON , ... leader in instrument development, custom automation, and contract manufacturing, ... of the Nanopatch™ needle-free drug delivery technology, have been ... development of the Nanopatch Jet Coating Instrument , ... delivery research and product development.  The award was announced ...
(Date:5/29/2015)... SAN DIEGO , May 29, 2015 /PRNewswire/ ... single cell sequencing data, from metastatic castrate resistant ... of the American Society for Clinical Oncology. This ... no cell left behind™ platform to ... study revealed that late stage patients have heterogeneous ...
(Date:5/28/2015)... Lilly and Company (NYSE: LLY ) announced today the ... up to $1.6 billion aggregate principal amount of certain of ... tendered, and did not validly withdraw, their notes on or ... time, on May 27, 2015 (the early tender date), and ... receive the total consideration. The total consideration for each series ...
Breaking Medicine Technology:Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... 2011 The Rottenstein Law Group, which represents clients with ... manufactured and sold by DePuy Orthopaedics, is fully in support ... of metal-on-metal joint implants. At a new set ... U.S. Food and Drug Administration states the following: ...
... VILLAGE, Nev., March 7, 2011   PDL BioPharma, ... guidance for the first quarter ending March 31, 2011 of ... million for the first quarter of 2010, an expected 34 ... the $10 million settlement received from UCB Pharma S.A. (UCB) ...
Cached Medicine Technology:Rottenstein Law Group Applauds New Efforts of U.S. FDA to Look More Carefully at Metal-on-Metal Implants After DePuy Recall 2PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 2PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 3PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 4
(Date:5/29/2015)... May 29, 2015 Johnson & ... a confidential Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) settlement ... due to his use of the antipsychotic medication. ... selected for the third bellwether trial to involve ... litigation underway in Pennsylvania’s Philadelphia Court of Common ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 The ... the graduates of its Advanced Training Program (ATP) ... who fill roles in their health care organization ... theory and methodology of continuous quality improvement in ... sister-program to Dr. Brent James’ internationally recognized Advanced ...
(Date:5/29/2015)... A group of doctors have discovered “The Cure ... to teach this “new math” to children in early childhood ... by the recent implementation of Common Core Math in classrooms ... Core is now a reality in children’s classrooms in 44 ... seeking ways to improve common core math training for their ...
(Date:5/29/2015)... 2015 World Patent Marketing, a vertically ... it has signed a 10 year licensing agreement for ... to let people learn about any topic and get ... "This is an exciting day for World Patent Marketing ... Cooper, CEO and Creative Director of World Patent Marketing, ...
(Date:5/29/2015)... FL (PRWEB) May 29, 2015 ... Utah, recently partnered with Stratus Video ... which will facilitate better communication and timely ... (LEP) and hearing loss. Stratus’ video remote ... in-house translators, enabling staff to quickly access ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3Health News:HORNE LLP’s Healthcare Delivery Institute Graduates Class from the Advanced Training Program 2Health News:Doctors Discover a Cure for the Common Core 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 4Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 5Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4
... , ... ... ... , ...
... ... ... ... ...
... MS Awareness Week March 8-14 is the ... someone is newly diagnosed every hour of every day. Supported by a Congressional resolution, this year ... world free of MS! , ... March 8, 2010 -- MS Awareness Week March 8-14 is the time for the nation ...
... , ... ... ... ...
... ... pictures that are better than anything that’s come before. With the new technology they’ve developed, ... in the heart and the major arteries around it. , ... Madison, WI (PRWEB) March 8, 2010 -- What does the ...
... ... announced today they have been named as the preferred distributor of Gendron bariatric care ... Gendron bariatric care medical equipment to healthcare professionals who wish to purchase or lease. ... Issaquah, WA. ...
Cached Medicine News:Health News:World Cocoa Foundation Launches Cocoa Livelihoods Program in Nigeria 2Health News:World Cocoa Foundation Launches Cocoa Livelihoods Program in Nigeria 3Health News:World Cocoa Foundation Launches Cocoa Livelihoods Program in Nigeria 4Health News:World Cocoa Foundation Launches Cocoa Livelihoods Program in Nigeria 5Health News:Beverage Industry Delivers On Commitment to Remove Regular Soft Drinks In Schools, Driving 88% Decline In Calories 2Health News:Beverage Industry Delivers On Commitment to Remove Regular Soft Drinks In Schools, Driving 88% Decline In Calories 3Health News:Beverage Industry Delivers On Commitment to Remove Regular Soft Drinks In Schools, Driving 88% Decline In Calories 4Health News:Beverage Industry Delivers On Commitment to Remove Regular Soft Drinks In Schools, Driving 88% Decline In Calories 5Health News:Beverage Industry Delivers On Commitment to Remove Regular Soft Drinks In Schools, Driving 88% Decline In Calories 6Health News:Beverage Industry Delivers On Commitment to Remove Regular Soft Drinks In Schools, Driving 88% Decline In Calories 7Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 2Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 3Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 4Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 5Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 6Health News:I'm Not Crazy...I'm Just Not You 2Health News:I'm Not Crazy...I'm Just Not You 3Health News:I'm Not Crazy...I'm Just Not You 4Health News:I'm Not Crazy...I'm Just Not You 5Health News:I'm Not Crazy...I'm Just Not You 6Health News:Heart Aflutter? Remarkable New Images Show What it Looks Like in 4-D 2Health News:Heart Aflutter? Remarkable New Images Show What it Looks Like in 4-D 3Health News:QuickMedical Launches New Line of Medical Equipment for Bariatric Care 2Health News:QuickMedical Launches New Line of Medical Equipment for Bariatric Care 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: